Rotavirus disease in Uzbekistan: Cost-effectiveness of a new vaccine

Isakbaeva, Elmira T.; Musabaev, Erkin; Antil, Lynn; Rheingans, Richard; Juraev, R.; Glass, Roger I.; Bresee, Joseph S.

doi:10.1016/j.vaccine.2006.07.029

Cited by 59 publications

(55 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, Fischer et al Reported that the total direct costs of diarrhea in children younger than 5 years in Vietnam were approximately $4 million in 2004 [7], but the population of Vietnam is around 25 times higher than that of Albania. In Uzbekistan, the hospitalization cost of a diarrhea case was about $77.8 in 2004 [13] whereas we report an average hospitalization cost of $229 per case. However, costs associated with diarrhea are obviously lower compared to developed countries such as US [12] and Australia [14], where costs per hospitalized diarrhea case amount to several thousand dollars.…”

Section: Discussionmentioning

confidence: 55%

“…As suggested in the literature, rotavirus is a very common cause of severe diarrhea and hospitalization for children under age of five in developed [12,14,16] and developing countries [4]. Numerous studies have shown that rotavirus immunization programs might be cost-effective, even though many aspects have to be taken into consideration such as morbidity and mortality rates due to rotavirus and vaccine price [7,12,13,15]. Besides the actual costs of diarrhea, these very important aspects related to rotavirus immunization should be investigated through carefully designed future studies, in order to help the decision makers to opt for a vaccination program or other potential interventions.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Diarrhea Associated Costs among Children Less Than 5 Years of Age from Health Care Provider and Social Perspectives in Albania

Ahmeti

Simaku

Preza

et al. 2013

Open Access Maced J Med Sci

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 55%

Section: Discussionmentioning

confidence: 99%

Diarrhea Associated Costs among Children Less Than 5 Years of Age from Health Care Provider and Social Perspectives in Albania

Ahmeti

Simaku

Preza

et al. 2013

Open Access Maced J Med Sci

View full text Add to dashboard Cite

show abstract

“…68 The input values were generally consistent within countries (except for France and Netherlands), because most values were obtained from the same local data sources. However, hospitalization rates were often surrounded with uncertainty, related to under-reporting in hospital statistics and the fact that the presence of RV is not systematically tested in cases of gastroenteritis.…”

Section: Assumptions and Inputs Of Economic Evaluationsmentioning

confidence: 90%

A critical literature review of health economic evaluations of rotavirus vaccination

Aballéa

Millier

Quilici

et al. 2013

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…However, recent developments suggest that the situation is improving: Two low-income countries, Uzbekistan and Kyrgyzstan have started hospital surveillance for rotavirus, albeit with low overall coverage. Uzbekistan has recently undertaken a cost-effectiveness study for rotavirus vaccination [19]. Azerbaijan, Georgia, Tajikistan and Ukraine initiated sentinel hospital surveillance in late 2006.…”

Section: Community and Hospital Burdenmentioning

confidence: 99%

Survey of rotavirus surveillance, laboratory capacity and disease burden in the eastern part of the WHO European Region

Williams

Gray²,

Pebody³

et al. 2008

Eurosurveillance

View full text Add to dashboard Cite

E U ROSU R V E I L L A N C E Vol . 13 · I ssu es 7-9 · J ul -Sep 20 08 · w w w. e urosurve illance. o rg 1 R e s e a r c h a r ti c l e s S u r v e y o f r o tav i r u S S u r v e i l l a n c e , l a b o r at o r y c a p a c i t y a n d d i S e a S e b u r d e n i n t h e e a S t e r n p a r t o f t h e W h o e u r o p e a n r e g i o n C J Williams (christopher.williams@norfolk.nhs.uk) 1,2 , Jim Gray 1 , R G Pebody 1 , A Lobanov 3 1. Health Protection Agency Centre for Infections, London, United Kingdom 2. European Training Programme for Intervention Epidemiology (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden 3. World Health Organization Regional Office for Europe, Copenhagen, Denmark (former staff member)Following the licensure of two rotavirus vaccines in Europe, we aimed to assess factors, such as surveillance, disease burden and laboratory capacity, which will be relevant for making decisions about rotavirus vaccine introduction in the different countries. We conducted an email-based survey of the national public health bodies in the World Health Organization (WHO) European Region in 2006 and report here the results from the 23 countries in the eastern part of the region. The survey included questions on rotavirus surveillance, laboratory capacity, burden (in children under the age of five years) and intention to introduce rotavirus vaccination. Countries were grouped into the four per-capita income categories defined by the World Bank. Fourteen of the 23 countries responded to the survey. All except one country reported that less than a quarter of their laboratories had rotavirus diagnostic capacity. Four countries had some form of specific rotavirus surveillance, but half were of very limited coverage. Ten countries did not report data on the incidence of rotavirus hospital admissions, although nine were able to report some data on rotavirus burden. Six of the responding countries said they were likely to introduce universal rotavirus vaccination. Rotavirus surveillance and laboratory capacity in the eastern part of the WHO European Region is limited but most countries had some estimate of rotavirus burden, often from special studies. The reported mortality rates were lower than those from a WHO mortality data source. Many countries in the eastern part of WHO European Region face a number of challenges before vaccine implementation, including strengthening surveillance, improving laboratory capacity and addressing financial barriers. IntroductionThe recent publication of the results of phase III trials of two oral rotavirus vaccines [1,2] showed vaccines that were effective in preventing serious clinical end points of rotavirus infection. The vaccines provide 85-95% protection against rotavirus infections severe enough to require hospitalisation, and 72-74% protection against all rotavirus infections [1,2]. However, vaccination appeared to protect only against disease, not to reduce the overall incidence of rotavirus gastrointestinal infection in the target group [2,...

show abstract

Rotavirus disease in Uzbekistan: Cost-effectiveness of a new vaccine

Cited by 59 publications

References 11 publications

Diarrhea Associated Costs among Children Less Than 5 Years of Age from Health Care Provider and Social Perspectives in Albania

Diarrhea Associated Costs among Children Less Than 5 Years of Age from Health Care Provider and Social Perspectives in Albania

A critical literature review of health economic evaluations of rotavirus vaccination

Survey of rotavirus surveillance, laboratory capacity and disease burden in the eastern part of the WHO European Region

Contact Info

Product

Resources

About